Aurinia Pharmaceuticals Inc. (AUPH) Trading 8.2% Higher
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) traded up 8.2% during mid-day trading on Friday . The stock traded as high as $2.15 and last traded at $2.11, with a volume of 1,404,733 shares traded. The stock had previously closed at $1.95.
Several equities research analysts have issued reports on the stock. HC Wainwright raised their price objective on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, August 17th. Leerink Swann restated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday, August 16th. FBR & Co restated an “outperform” rating and set a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aurinia Pharmaceuticals has an average rating of “Buy” and an average price target of $7.75.
The firm’s 50 day moving average price is $2.84 and its 200-day moving average price is $2.75. The firm’s market capitalization is $72.34 million.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.